Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Masri A, Cappelli F, Davis MK, Fontana M, Garcia-Pavia P, Gillmore JD, Hanna M, Obici L, Solomon SD, Sperry BW, Tahara N, Waddington-Cruz M, Kristen AV, Falk RH, Shah SJ, Nativi-Nicolau J, Viney NJ, Yang Q, Chen J, Tsimikas S, Maurer MS

Open source

DOI: 10.1161/circheartfailure.126.014205
Published: 2026 Jun
Container: Circulation. Heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1161/circheartfailure.126.014205,
  title = {Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.},
  author = {Masri A and Cappelli F and Davis MK and Fontana M and Garcia-Pavia P and Gillmore JD and Hanna M and Obici L and Solomon SD and Sperry BW and Tahara N and Waddington-Cruz M and Kristen AV and Falk RH and Shah SJ and Nativi-Nicolau J and Viney NJ and Yang Q and Chen J and Tsimikas S and Maurer MS},
  year = {2026},
  journal = {Circulation. Heart failure},
  doi = {10.1161/circheartfailure.126.014205},
  url = {https://doi.org/10.1161/circheartfailure.126.014205}
}

RIS

TY  - JOUR
TI  - Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
AU  - Masri A
AU  - Cappelli F
AU  - Davis MK
AU  - Fontana M
AU  - Garcia-Pavia P
AU  - Gillmore JD
AU  - Hanna M
AU  - Obici L
AU  - Solomon SD
AU  - Sperry BW
AU  - Tahara N
AU  - Waddington-Cruz M
AU  - Kristen AV
AU  - Falk RH
AU  - Shah SJ
AU  - Nativi-Nicolau J
AU  - Viney NJ
AU  - Yang Q
AU  - Chen J
AU  - Tsimikas S
AU  - Maurer MS
PY  - 2026
JO  - Circulation. Heart failure
DO  - 10.1161/circheartfailure.126.014205
UR  - https://doi.org/10.1161/circheartfailure.126.014205
ER  -

APA

A, M., F, C., MK, D., M, F., P, G., JD, G., M, H., L, O., SD, S., BW, S., N, T., M, W., AV, K., RH, F., SJ, S., J, N., NJ, V., Q, Y., J, C., S, T., & MS, M. (2026). Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.. Circulation. Heart failure. https://doi.org/10.1161/circheartfailure.126.014205

Source records

pubmed · retrieved 2026-09-27T09:10:09.325Z